Golimumab Therapy in Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-α) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-α agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis. (Korean J Gastroenterol 2016;67:64-73).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
The Korean Journal of Gastroenterology - 67(2016), 2, Seite 64-73 |
| Sprache: |
Englisch ; Koreanisch |
|---|
| Beteiligte Personen: |
Won Moon [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adalimumab |
|---|
| doi: |
10.4166/kjg.2016.67.2.64 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ048163694 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ048163694 | ||
| 003 | DE-627 | ||
| 005 | 20230503011934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4166/kjg.2016.67.2.64 |2 doi | |
| 035 | |a (DE-627)DOAJ048163694 | ||
| 035 | |a (DE-599)DOAJc03ac3d8719f487d995e61c55938a476 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a kor | ||
| 100 | 0 | |a Won Moon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Golimumab Therapy in Ulcerative Colitis |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-α) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-α agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis. (Korean J Gastroenterol 2016;67:64-73) | ||
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 4 | |a Tumor necrosis factor-alpha | |
| 650 | 4 | |a Infliximab | |
| 650 | 4 | |a Adalimumab | |
| 650 | 4 | |a Golimumab | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 773 | 0 | 8 | |i In |t The Korean Journal of Gastroenterology |d Jin Publishing & Printing Co., 2019 |g 67(2016), 2, Seite 64-73 |w (DE-627)DOAJ000143707 |x 22336869 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2016 |g number:2 |g pages:64-73 |
| 856 | 4 | 0 | |u https://doi.org/10.4166/kjg.2016.67.2.64 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/c03ac3d8719f487d995e61c55938a476 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.kjg.or.kr/journal/view.html?doi=10.4166/kjg.2016.67.2.64 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1598-9992 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2016 |e 2 |h 64-73 | ||